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AbstrAct
Objective Our aims were to assess the association of 
dairy intake with prevalence of metabolic syndrome (MetS) 
(cross- sectionally) and with incident hypertension and 
incident diabetes (prospectively) in a large multinational 
cohort study.
Methods The Prospective Urban Rural Epidemiology 
(PURE) study is a prospective epidemiological study of 
individuals aged 35 and 70 years from 21 countries on 
five continents, with a median follow- up of 9.1 years. In 
the cross- sectional analyses, we assessed the association 
of dairy intake with prevalent MetS and its components 
among individuals with information on the five MetS 
components (n=112 922). For the prospective analyses, 
we examined the association of dairy with incident 
hypertension (in 57 547 individuals free of hypertension) 
and diabetes (in 131 481 individuals free of diabetes).
Results In cross- sectional analysis, higher intake of 
total dairy (at least two servings/day compared with zero 
intake; OR 0.76, 95% CI 0.71 to 0.80, p- trend<0.0001) 
was associated with a lower prevalence of MetS after 
multivariable adjustment. Higher intakes of whole fat 
dairy consumed alone (OR 0.72, 95% CI 0.66 to 0.78, 
p- trend<0.0001), or consumed jointly with low fat dairy 
(OR 0.89, 95% CI 0.80 to 0.98, p- trend=0.0005), were 
associated with a lower MetS prevalence. Low fat dairy 
consumed alone was not associated with MetS (OR 
1.03, 95% CI 0.77 to 1.38, p- trend=0.13). In prospective 
analysis, 13 640 people with incident hypertension and 
5351 people with incident diabetes were recorded. Higher 
intake of total dairy (at least two servings/day vs zero 
serving/day) was associated with a lower incidence of 
hypertension (HR 0.89, 95% CI 0.82 to 0.97, p- trend=0.02) 
and diabetes (HR 0.88, 95% CI 0.76 to 1.02, p- trend=0.01). 
Directionally similar associations were found for whole fat 
dairy versus each outcome.
Conclusions Higher intake of whole fat (but not low fat) 
dairy was associated with a lower prevalence of MetS and 
most of its component factors, and with a lower incidence 
of hypertension and diabetes. Our findings should be 
evaluated in large randomized trials of the effects of whole 
fat dairy on the risks of MetS, hypertension, and diabetes.
InTROduCTIOn
Metabolic syndrome (MetS) is characterized 
by the common clustering of five metabolic 
abnormalities, including elevated blood 
significance of this study
What is already known about this subject?
 ► Several cohort studies found that higher dairy in-
take is associated with lower risk of metabolic syn-
drome (MetS), diabetes, and hypertension. To date, 
most studies were conducted in North America and 
Europe, with limited information from other world 
regions (eg, China, India, South America, and Africa).
What are the new findings?
 ► Higher intake of whole fat (but not low fat) dairy was 
associated with a lower prevalence of MetS and 
most of its component factors, and with a lower inci-
dence of hypertension and diabetes.
How might these results change the focus of 
research or clinical practice?
 ► Our findings should be evaluated in large random-
ized trials of the effects of whole fat dairy on the 
risks of MetS, hypertension, and diabetes.
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pressure, abdominal obesity, elevated triglycerides, low 
high density lipoprotein (HDL) cholesterol, and elevated 
blood glucose. The presence of MetS is associated with an 
increased risk of cardiovascular disease, type 2 diabetes, 
and mortality.1 Diet may play an important role in the 
development of MetS and diabetes.2–4 Dairy products in 
particular have been studied in relation to blood lipids, 
blood pressure, and cardiovascular disease.5 In several 
short- term trials, dairy intake was found to lower blood 
pressure,6 7 but less is known about its influence on blood 
glucose.8 9 Emerging evidence suggests that dairy foods, 
particularly whole fat dairy and fermented dairy (eg, 
cheese or yogurt), may influence diverse pathways and 
have favorable metabolic effects.10 Additionally, several 
cohort studies have shown that higher dairy consump-
tion is associated with lower risk of MetS, diabetes, and 
hypertension.5 11 12 To date, most cohort studies have 
been conducted in North America and Europe, with 
limited information from other world regions (eg, China, 
India, South America, and Africa), which have substan-
tially different diets and different amounts and types of 
dairy intake than in high income countries and may limit 
the generalizability of previous findings.
The primary aim of this analysis from the Prospective 
Urban Rural Epidemiology (PURE) study was to assess 
the association of dairy intake with prevalence of MetS 
(cross -sectional analysis) and to examine the associa-
tion of dairy intake with incident hypertension and inci-
dent diabetes after 9.1 years of follow- up (prospective 
analyses).
MeTHOds
study design and participants
The design and methods of the PURE study have been 
described previously.13 14 Briefly, PURE is a large- scale 
cohort study of participants aged 35 and 70 years using 
an unbiased approach of sampling individuals from 664 
communities in 21 countries (Argentina, Bangladesh, 
Brazil, Canada, Chile, China, Colombia, India, Iran, 
Malaysia, occupied Palestine territory, Pakistan, Phil-
ippines, Poland, South Africa, Saudi Arabia, Sweden, 
Tanzania, Turkey, United Arab Emirates, and Zimbabwe). 
Details of study design and sampling are described in 
online supplementary appendix (page 10). The protocol 
was approved by the ethics committee at each partic-
ipating center and all participants provided written 
informed consent.
Procedures
Participants’ habitual food intake was recorded using 
country- specific (region- specific in India) validated food 
frequency questionnaires (FFQs; online appendix table 
S1). For almost all countries where a validated FFQ was 
not available, we developed and validated FFQs using 
a standard method. The FFQ was undertaken by inter-
view together with other questionnaires at the PURE 
study baseline. The FFQ recorded the number of times 
participants had consumed any specific items from a list 
of foods in the past year. The FFQs had the same format 
for all countries. Total dairy included milk, yogurt, yogurt 
drink, cheese, and mixed dishes prepared with dairy. 
Mixed dishes prepared with dairy were disaggregated 
into their constituents and a proportional weight was 
assigned to each component. We further grouped these 
foods into whole fat dairy (whole milk, whole fat yogurt, 
whole fat cheese, whole fat yogurt drinks, and mixed 
dishes prepared with whole f at dairy products) and 
low fat dairy (low fat (1–2%) milk, skimmed milk, low 
fat yogurt, low fat cheese, and low fat yogurt drink). To 
ensure that measurements were consistent across coun-
tries we used daily standard serving intake of each dairy 
product. Butter and cream were not included in the total 
dairy and whole fat dairy groups and their associations 
are reported separately. Butter intake was not recorded 
as an item on the FFQ in China, Malaysia, Sweden, and 
occupied Palestine territory, and therefore, the associa-
tion between butter and outcomes was assessed only in 
those countries where butter intake was recorded.
Information on personal medical history, use of 
prescription medications, education level, and smoking 
status was recorded using a standardized question-
naire.13 14 Physical measurements included weight, 
height, waist and hip circumferences, and two record-
ings of resting blood pressure with the use of an Omron 
HEM-757 automatic digital monitor (Omron Corp, 
Tokyo, Japan) were recorded in all participants. A fasting 
blood sample was collected and frozen at between –20 
and –70°C. All blood samples were shipped in ambient 
packaging with the use of STP-250 shipping boxes (Saf- 
T- Pak, AnInmark Company, Edmonton, AB, Canada) to 
the Clinical Research and Clinical Trials Laboratory at 
Hamilton General Hospital (Hamilton, ON, Canada) or 
the regional laboratories in Beijing (China), Bangalore 
(India), or Kocaeli (Turkey), for analyses with the use 
of validated and standardized methods.15 Fasting blood 
samples were analyzed for total cholesterol, low density 
lipoprotein cholesterol (LDL- C), HDL cholesterol (HDL- 
C), triglycerides, apolipoprotein A1, and apolipoprotein 
B at the Population Health Research Institute.16
During follow- up, participants were contacted at least 
once every three years either by telephone or in person 
visits by the local research team. Case- report forms 
recorded details about events and these were obtained 
either from medical records or by interviewing partici-
pants. During the follow- up, participants were asked 
if they had been diagnosed with hypertension or were 
on antihypertensive medications. Participants were 
also asked if they had developed diabetes since the last 
follow- up (self- reported diabetes, or on oral hypogly-
cemic agents). We did not record lipids or waist circum-
ference routinely during follow- up in all individuals and 
so we are not able to report on incident MetS.
A total of 153 220 participants from 21 countries 
completed the FFQ at baseline, of whom 147 812 had 
plausible energy intake (500–5000 kcal/day).17–19 For 
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the cross- sectional analysis, among individuals with infor-
mation on the five MetS components (n=112 922), we 
assessed the association of dairy intake with prevalent 
MetS and its components. For the prospective analysis, we 
examined the association of dairy with incident hyper-
tension (n=57 547 individuals free of hypertension) and 
diabetes (n=131 481 individuals free of diabetes) after 9.1 
years of follow- up. The analysis of incident hypertension 
included fewer individuals because 64 978 individuals or 
44% who had hypertension at baseline were no longer 
at risk for incident hypertension during follow- up. Of 
the 82 834 participants without baseline hypertension, 
25 287 (30%) were excluded because blood pressure was 
not recorded in all participants during follow- up. The 
blood pressure measures during follow- up were carried 
out systematically in all participants in 16 countries or 
in a random 20% of participants in five countries. In 
the latter group of countries, the individuals without 
blood pressure measures during follow- up did not differ 
from individuals with blood pressure measures during 
follow- up (online appendix table S2).
Outcome definitions
The MetS was determined based on five component 
factors: (1) elevated blood pressure, (2) elevated waist 
circumference, (3) low HDL- C), (4) elevated blood 
triglycerides, and (5) elevated fasting blood glucose. 
Participants with at least three of the following five 
component factors were classified as having MetS at 
baseline.1
1. Elevated blood pressure: blood pressure lowering 
medication or systolic blood pressure (SBP)≥130 mm 
Hg, or diastolic blood pressure (DBP)≥85 mm Hg.
2. Elevated waist circumference: waist greater than 80 cm 
in women, and at least 94 cm in men (except among 
Asians or South Americans in whom a waist circumfer-
ence of ≥90 cm was used).
3. Reduced HDL- C: HDL- C<1 mmol/dL (40 mg/dL) 
among men or HDL- C<1.3 mmol/L (50 mg/dL) 
among women.
4. Elevated triglycerides: triglycerides>1.7 mmmol/dL 
(150 mg/dL).
5. Elevated fasting blood glucose: fasting glu-
cose≥5.5 mmol/L (100 mg/dL) or those on oral hypo-
glycemic agents.
Metabolic syndrome was defined as the presence of 
any three of the above five components.1
During follow- up, incident hypertension was defined 
as self- reported diagnosis of hypertension or prescribed 
antihypertensive medications, or having a SBP>140 mm 
Hg or a DBP>90 mm Hg.20 Incident diabetes was 
defined as self- reported diabetes, or prescribed an oral 
hypoglycemic agents, or having a fasting glucose of 
≥7.0 mmol/L).21
statistical analysis
Continuous variables were expressed as means (SD) 
and categorical variables as percentages. Education was 
categorized as none or primary school (first 6 years of 
age), secondary school (7–11 years of age), and college, 
trade school, or university (>11 years of age). Smoking 
status was categorized as never, former, or current. Phys-
ical activity was categorized based on the metabolic 
equivalent of task (MET) per min per week into low 
(<600 MET min per week), moderate (600–3000 MET 
min per week), and high (>3000 MET min per week) 
activity. The mean and median intakes of total dairy were 
calculated, overall and by geographical region. Partici-
pants were categorized into intake groups based on total 
dairy intakes of zero, less than one serving/day, one to 
two servings/day, and more than two servings/day (with 
the lowest intake group used as the reference). Categories 
for milk, yogurt, cheese, and butter consumption were 
zero, less than half a serving/day, half to one serving/
day, and more than one serving/day. We used standard 
serving sizes for each dairy product. For example, a 
glass of milk or a cup of yogurt was 244 g, one slice of 
cheese was 15 g, and a teaspoon of butter was 5 g.19 In the 
cross- sectional analyses, we used multilevel mixed- effects 
linear regression models to calculate the adjusted mean 
SBP and DBP, waist circumference, blood lipids (LDL- C, 
HDL- C, triglycerides, apolipoprotein A, apolipoprotein 
B, ratio of apolipoprotein B to apolipoprotein A), and 
fasting glucose at baseline by category of dairy intake 
using multilevel mixed- effects linear regression models. 
Odds ratios were calculated to evaluate the associations 
between dairy intake and MetS, and each component 
of MetS (elevated blood pressure, low HDL- C, elevated 
waist circumference, elevated triglycerides, and elevated 
blood glucose) using logistic regression models. For 
models of each individual component of MetS except 
for waist circumference, we adjusted for age (continuous 
variable), sex, body mass index (continuous variable), 
smoking status, urban or rural residence, education, phys-
ical activity, energy intake, quintiles of fruits, vegetables, 
and percent energy from carbohydrate consumption, and 
study center (as a random intercept). The use of center 
as a random intercept takes into account clustering by 
country (which automatically adjusts for country, and 
more specifically, centers within each country). For waist 
circumference and MetS, we ran the same model but 
excluded body mass index, to avoid collinearity. When we 
evaluated intakes of starchy foods as a covariate in place 
of percent energy from carbohydrates, findings were not 
materially altered (online appendix table S3).
For the prospective data, we calculated hazard ratios 
using multivariable Cox frailty model with random inter-
cepts to account for center clustering (which also adjusts 
for country) to evaluate the association of dairy intake 
with incident hypertension and incident diabetes. Multi-
variable models for incident hypertension and incident 
diabetes were adjusted for age (continuous variable), 
sex, body mass index (continuous variable), education, 
smoking status, urban or rural residence (location), phys-
ical activity, energy intake, quintiles of percent energy 
from carbohydrates, vegetable and fruit intake, and study 
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center as random intercept. For incident diabetes, we 
additionally adjusted for family history of diabetes. The 
proportional hazards assumption was checked by visual 
inspection of log–log plots. We used restricted cubic- 
spline analyses to test for non- linearity of the association 
between dairy intake and incident diabetes. For signif-
icant non- linear associations, the p values for overall 
significance of the association is reported, whereas asso-
ciations with no evidence of non- linearity were character-
ized by tests for linear trend.
Since the amount and types of dairy foods differ across 
world regions (eg, intake of dairy is highest in Europe and 
North America, South America and the Middle East, and 
lowest in China, South Asia, Southeast Asia, and Africa), 
we conducted subgroup analyses to examine associations 
between dairy and outcome events according to low 
versus high dairy intake regions. Additionally, we exam-
ined whether the associations were similar across seven 
geographical regions, among those consuming higher or 
lower levels of sodium or potassium and those consuming 
higher or lower servings of fruits and vegetables, as these 
factors may influence associations with MetS, hyperten-
sion, and diabetes. The likelihood ratio test was used to 
test for heterogeneity of associations across subgroups.
In sensitivity analyses, to assess the association between 
whole fat and low fat dairy intake with outcomes, partic-
ipants were stratified based on the predominant type of 
dairy intake and four mutually exclusive groups were 
created. In our FFQs, the frequency of consumption as 
never or less than once per month was used as an indi-
cator for food items never or rarely consumed. Therefore, 
whole fat dairy intake was defined as an intake of whole 
fat dairy of one serving or more per month and an intake 
of low fat dairy of less than one serving per month. Intake 
of more than one serving of low fat dairy per month and 
less than one serving of whole fat dairy per month was 
defined as low fat dairy intake. However, our study was 
underpowered to detect an association separately in this 
subgroup owing to a low number of participants in this 
particular group. Both low fat and whole fat dairy intakes 
were defined as intake of at least one serving of whole 
fat dairy and one serving of low fat dairy per month. 
Individuals whose intake of dairy was reported to be less 
than once per month or never were considered as having 
no intake. In each group, the lowest intake was used as 
the reference group. Models for whole dairy intake are 
adjusted for low fat dairy intake and vice versa.
For risk estimates showing relative risk decrease or 
increase of more than 10% (eg, HR<0.90 or >1.10) 
but with a non- significant p- value for trend, we consid-
ered estimates to be directionally associated with health 
outcomes. This magnitude threshold was used to reflect 
the strength of association expected for dietary expo-
sures versus metabolic risk markers or outcomes, and 
would be of importance for population health. In tests 
for trend, we used the median dairy intake value in each 
of the categories of dairy intake and included the vari-
able as a quantitative predictor.
Role of the funding source
The external funders of the study had no role in study 
design, data collection, analysis, interpretation, or writing 
of the report. The corresponding and senior authors 
had full access to all the data in the study and had final 
responsibility for the decision to submit for publication.
ResulTs
Mean (±SD) total dairy intake was 179.0 (224.1) g/day, 
with whole fat dairy consumption almost twice as high 
as low fat dairy intake (124.6 vs 65.0 g/day) (table 1). 
Highest intakes of total dairy were found in Europe/
North America, Middle East, and South America, while 
the lowest intakes were in South Asia, China, Africa, and 
Southeast Asia. Low fat dairy consumption was higher 
than whole fat dairy in North America and Europe, while 
other regions of the world consumed markedly higher 
whole fat than low fat dairy (table 1; online appendix 
table S4). There were also marked differences in body 
mass index, physical activity, and education among partic-
ipants across regions, with body mass index being highest 
in the Middle East and South America, physical activity 
highest in South America, North America, and Europe, 
and a college education most common in North America 
and Europe.
At baseline, 78 533 (56%) individuals had elevated 
blood pressure, 67 897 (48%) had elevated waist circum-
ference, 63 415 (53%) had low HDL- C, 35 595 (30.2%) 
had elevated triglycerides, and 33 082 (27.8%) had 
elevated blood glucose. A total of 46 667 (41.3%) were 
classified as having MetS (table 1).
dairy intake and prevalence of metabolic syndrome
Higher dairy intake (at least two servings/day vs zero 
intake) was associated with lower mean SBP and DBP, 
waist circumference, body mass index, triglycerides, ratio 
of triglycerides to HDL- C, and blood glucose, adjusting 
for covariates (table 2). No significant association 
between dairy intake and HDL- C levels was found, while 
LDL cholesterol (LDL- C) levels were higher. There was 
no significant association between dairy intake and other 
cardiovascular risk markers (table 2).
Higher intakes of total dairy (OR 0.76, 95% CI 0.71 to 
0.80, p- trend<0.0001), whole fat dairy alone (OR 0.72, 
95% CI 0.66 to 0.78, p- trend<0.0001), and whole fat and 
low fat dairy consumed jointly (OR 0.89, 95% CI 0.80 to 
0.98, p- trend=0.0005) were each associated with a lower 
prevalence of MetS, adjusting for covariates (figure 1). 
No association between low fat dairy and prevalence of 
MetS was found (OR 1.03, 95% CI 0.77 to 1.38).
Total dairy and whole fat dairy, but not low fat dairy, 
were also associated with a lower prevalence of most MetS 
components, including elevated blood pressure, elevated 
waist circumference, elevated triglycerides, and elevated 
blood glucose. No significant association was found for 
low HDL- C with total, whole fat or low fat dairy (figure 1).










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6 BMJ Open Diab Res Care 2020;8:e000826. doi:10.1136/bmjdrc-2019-000826
Epidemiology/Health Services Research









Systolic blood pressure (mm Hg) 133.2 (0.74) 131.8 (0.73) 130.9 (0.74) 130.3 (0.74)   <0.0001
Diastolic blood pressure (mm Hg) 83.8 (0.57) 82.7 (0.56) 82.2 (0.57) 81.8 (0.57)   <0.0001
Waist circumference (cm) 85.8 (0.37) 85.7 (0.36) 85.5 (0.36) 85.2 (0.37)   <0.0001
Body mass index (kg/m2) 26.8 (0.33) 26.6 (0.32) 26.6 (0.32) 26.3 (0.33)   <0.0001
HDL- C (mmol/L) 1.21 (0.016) 1.21 (0.016) 1.21 (0.016) 1.21 (0.016)   0.133
Triglyceride (mmol/L) 1.55 (0.04) 1.55 (0.03) 1.53 (0.03) 1.49 (0.04)   <0.0001
Fasting glucose (mmol/L) 5.33 (0.07) 5.34 (0.07) 5.30 (0.07) 5.26 (0.07)   0.001
Total cholesterol (mmol/L) 4.87 (0.05) 4.91 (0.05) 4.91 (0.05) 4.89 (0.05)   0.170
LDL- C (mmol/L) 3.03 (0.05) 3.08 (0.05) 3.08 (0.05) 3.06 (0.05)   0.03
Total cholesterol to HDL- C ratio 4.22 (0.06) 4.25 (0.06) 4.26 (0.06) 4.24 (0.06)   0.16
Triglyceride to HDL- C ratio 1.45 (0.04) 1.44 (0.04) 1.44 (0.04) 1.40 (0.04)   0.02
ApoA1 (µmol/L) 1.50 (0.02) 1.50 (0.02) 1.49 (0.02) 1.49 (0.02)   0.06
ApoB (µmol/L) 1.00 (0.01) 1.02 (0.01) 1.02 (0.01) 1.00 (0.01)   0.03
ApoA to ApoB ratio 0.70 (0.02) 0.71 (0.01) 0.71 (0.01) 0.70 (0.01)   0.59
Mean systolic and diastolic blood pressure were adjusted for age, sex, body mass index, blood pressure medication, smoking, location 
(urban/rural), education, physical activity, fruit and vegetable intake, percent energy from carbohydrates, energy and study center as random 
effect.
Mean waist circumferences was adjusted for age (continuous), sex, BMI (continuous), smoking, location (urban/rural), education, physical 
activity, energy intake, quintiles of fruits and vegetables, percent energy from carbohydrates consumption, and study center as random 
effect.
Mean body mass index was adjusted for age (continuous), sex, smoking, location (urban/rural), education, physical activity, energy intake, 
quintiles of fruits and vegetables, percent energy from carbohydrates consumption, and study center as random effect.
Mean HDL- C was adjusted for age (continuous), sex, body mass index (continuous), smoking, cholesterol and statin medication, location 
(urban/rural), education, physical activity, energy intake, quintiles of fruits and vegetables, percent energy from carbohydrates consumption, 
and study center as random effect.
Mean triglyceride was adjusted for age (continuous), sex, body mass index (continuous), smoking, statin medication, location (urban/rural), 
education, physical activity, energy intake, quintiles of fruits and vegetables, percent energy from carbohydrates consumption, and study 
center as random effect.
Mean fasting blood glucose was adjusted for age (continuous), sex, body mass index (continuous), smoking, diabetes medication, location 
(urban/rural), education, physical activity, energy intake, quintiles of fruits and vegetables, percent energy from carbohydrates consumption, 
and study center as random effect.
Mean total cholesterol, LDL- C, total cholesterol to HDL- C ratio, ApoA, ApoB, ApoA to ApoB ratio were adjusted for age, sex, body mass 
index, cholesterol medication, education, location (urban/rural), physical activity, energy intake, quintiles of fruits and vegetables, percent 
energy from carbohydrates consumption, and study center as random effect.
Apo, apolipoprotein; HDL- C, high density lipoprotein cholesterol; LDL- C, low density lipoprotein cholesterol.
With mutual adjustment of whole fat dairy and low fat 
dairy, higher whole fat dairy intake was associated with 
lower prevalence of MetS. By contrast, higher intake of low 
fat dairy was associated with a modestly higher prevalence 
of MetS (p- trend=0.05) and low HDL- C (p- trend=0.001), 
but also with a marginally lower prevalence of elevated 
triglycerides (p- trend=0.04) (online appendix table S5). 
Types of dairy foods (milk, yogurt, cheese, and butter) 
showed similar associations with lower MetS prevalence 
(online appendix figure S1).
The associations between dairy intake and MetS were 
consistent in regions with low dairy intake (China, 
South Asia, Southeast Asia, and Africa) and high 
dairy intake (North America/Europe, Middle East, 
and South America), but the magnitude of the asso-
ciation was stronger in the low dairy regions (p for 
heterogeneity=0.017) (online appendix figure S2). The 
association between dairy intake and MetS was indepen-
dent of sodium and potassium intake (online appendix 
figure S3).
dairy intake and risk of incident hypertension and diabetes
Of the 57 547 individuals without hypertension at base-
line, a total of 13 640 (23.7%) people with incident hyper-
tension were identified during follow- up. A total of 5351 
(4.1%) people with incident diabetes were identified 
during follow- up among the 131 481 individuals without 
diabetes.
Higher dairy intake (at least two servings/day vs zero 
intake) was associated with a lower incidence of hyper-
tension (HR 0.89, 95% CI 0.82 to 0.97, Pp- trend=0.02) 
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Figure 1 Association of (A) total dairy, (B) whole fat dairy alone, (C) low fat dairy alone and (D) among those who consumed 
both whole fat and low fat dairy with prevalent metabolic syndrome and its component (OR, 95% CI). Metabolic syndrome: 
defined as presence of any three of the four components: elevated blood pressure (defined as those on blood pressure 
lowering medication, or systolic blood pressure) ≥130 mm Hg or diastolic blood pressure (DBP) ≥85 mm Hg); elevated waist 
circumference (defined as women with waist >80 cm, men with waist ≥94 cm, except among Asians or South Americans 
in whom waist was ≥90 cm), reduced high density lipoprotein cholesterol (HDL- C) (defined as men on cholesterol lowering 
medications or with HDL- C<1 mmol/dL (40 mg/dL), or women with HDL- C<1.3 mmol/L (50 mg/dL)); elevated triglycerides 
(defined as triglyceride levels>1.7 mmmol/dL (150 mg/dL)); and elevated fasting blood glucose (defined as as those on 
glucose lowering medications or with a fasting glucose value ≥5.5 mmol/L). OR models for metabolic syndrome and waist 
circumference are adjusted for age (continuous), sex, smoking status, education, location, physical activity, energy intake, 
percent energy from carbohydrate, fruit and vegetable intake, and study center as random effect. Models for whole dairy intake 
are adjusted for low fat dairy intake and vice versa. OR model for elevated blood pressure, low HDL- C, elevated triglycerides 
and elevated fasting blood glucose are adjusted for age (continuous), sex, body mass index (continuous), smoking status, 
location, education, physical activity, energy intake, quintiles of percent energy from carbohydrate, fruit and vegetable intake, 
and study center as random effect. Models for whole dairy intake are adjusted for low fat dairy intake and vice versa. Panel (A) 
shows a significant inverse association between total dairy intake and metabolic syndrome and each of its components, except 
low HDL- C (no association); (B) shows a significant inverse association between whole fat dairy (alone) intake and metabolic 
syndrome, elevated blood pressure, elevated waist circumference, elevated triglycerides, and elevated fasting blood glucose. 
No association was observed between whole fat dairy and low HDL- C; (C) shows no association between low fat dairy (alone) 
intake and metabolic syndrome and its components, except elevated triglycerides and elevated fasting blood glucose (a trend 
towards lower prevalence); and (D) shows a significant inverse association between consumption of both whole fat and low 
fat dairy and metabolic syndrome, elevated blood pressure and elevated triglycerides, and no association with elevated waist 
circumference or HDL- C or elevated fasting blood glucose.
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Figure 2 Associations of (A) total dairy, (B) whole fat dairy alone, (C) low fat dairy alone, and (D) both whole fat and low 
fat dairy with incident hypertension and incident diabetes (HR, 95% CI). Incident hypertension was defined as self- reported 
hypertension, with or without use of antihypertensive medications or a systolic blood pressure of >140 mm Hg, or a diastolic 
blood pressure of >90 mm Hg.10 Incident diabetes was defined as self- reported diabetes, with or without use of oral 
hypoglycemic agents or insulin, or having a documented fasting glucose level of ≥7.0 mmol/L.11 Hypertension model adjusted 
for age (continuous), sex, body mass index (continuous), education, smoking status, location, physical activity, energy, 
quintiles of percent energy from carbohydrates, fruit and vegetable intake and study center as random effect. Models for 
whole dairy intake adjusted for low fat dairy intake and vice versa. Diabetesmodel adjusted for age (continuous), sex, body 
mass index (continuous), education, smoking status, location, family history of diabetes, physical activity, energy, quintiles 
of percent energy from carbohydrates, fruit and vegetable intake, and study center as random effect. Models for whole dairy 
intake are adjusted for low fat dairy intake and vice versa. Panel (A) shows a significant inverse association between total dairy 
and incident hypertension and a trend towards lower incidence of diabetes; (B) shows a trend towards lower incidence of 
hypertension and diabetes with higher intake of whole fat dairy (alone); (C) shows no association between low fat dairy intake 
(alone) and incident hypertension and incident diabetes; and (D) shows a trend towards lower incidence of hypertension and 
diabetes with higher intake of both whole fat and low fat dairy.
(figure 2) with directionally similar estimates found for 
whole fat and low fat dairy.
For diabetes, higher dairy intake (at least two servings/
day vs zero intake) was associated with a lower diabetes 
incidence (HR 0.88, 95% CI 0.76 to 1.02, p- trend=0.01) 
(figure 2) with directionally similar estimates with whole 
fat dairy (alone or with low fat) but not with low fat dairy 
alone.
When we used more than three servings/day as the 
highest intake category (instead of more than two 
servings/day), we found similar estimates of associa-
tion (for hypertension, HR 0.87,; 95% CI 0.79 to 0.96, 
p- trend=0.02; and for diabetes, HR 0.86, 95% CI 0.73 to 
1.02;, p- trend=0.01).
When we evaluated whole fat dairy intake and low fat 
dairy intake jointly adjusted for each other, higher whole 
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fat dairy intake was significantly associated with a lower 
incidence of hypertension and diabetes. In contrast, no 
significant associations were found for low fat dairy versus 
hypertension or diabetes (online appendix table S5).
The associations between types of dairy (milk, yogurt, 
cheese, and butter) showed directionally similar results 
with incident hypertension and incident diabetes (online 
appendix figure S4).
dIsCussIOn
In this large multinational prospective cohort study from 
21 countries located in five continents, higher dairy 
consumption was associated with lower mean blood 
pressure, waist circumference, triglycerides, and blood 
glucose. Additionally, total dairy and whole fat dairy 
intakes were associated with lower risk of MetS and its 
components. A similar pattern of results was found in 
those consuming diets that may influence blood pres-
sure, such as those with higher or lower levels of sodium 
and potassium, or varying levels of fruit and vegetable 
intake. During follow- up of nine years, higher consump-
tion of dairy was associated with lower risk of incident 
hypertension and incident diabetes. These results were 
clearer in those who consumed whole fat dairy than in 
those who consumed low fat dairy.
Short- term feeding trials showed a reduction in blood 
pressure with both low and whole fat dairy, and a reduc-
tion in triglycerides with whole fat,6 7 22 but the evidence 
for fasting blood glucose in these trials is inconsistent or 
inconclusive.8 9 Our results showed directionally consis-
tent inverse associations between consumption of various 
types of dairy foods (milk, yogurt, cheese, or butter) and 
MetS, especially for intake of whole fat dairy. Our find-
ings are consistent with recent meta- analyses of cohort 
studies of mostly Western and higher- income Asian popu-
lations (~10% lower risk of MetS per one serving increase 
in dairy).11 23–25 Further, in these meta- analyses the asso-
ciations were clearer for whole fat dairy (RR 0.78, 95% CI 
0.61 to 0.96), while no association was observed for low 
fat dairy and MetS,11 which is consistent with our find-
ings. In addition, a recent cohort study in Brazil found 
similar results.26
Our finding of a favorable association between butter 
and prevalence of MetS should be interpreted with 
caution, given that butter intake was very low (mean 
3.3 g/day). It is also noteworthy that butter was not 
included as one of the dairy products in the total dairy 
definition in our analyses, and so even if the association 
of butter with lower MetS is due to chance, the results on 
total dairy are robust.
In prospective analyses, we identified a significant 
inverse association between dairy intake and incident 
hypertension, which is consistent with a recent meta- 
analysis of cohort studies in mostly Western and some 
Asian populations,5 12 23 27 two short- term controlled 
feeding trials of dairy intake and blood pressure,6 7 and 
our prior report of lower risk of stroke with higher dairy 
consumption.28 Cohort studies in the US and Europe 
have found an association with lower risk of hypertension 
with higher dairy intake, especially yogurt.29 30 On the 
other hand, recent Mendelian randomization studies did 
not show that dairy intake is associated with lower hyper-
tension.31 Taken together, dairy foods should be evalu-
ated in large randomized trials of dairy intake and longer 
term blood pressure change or risk of hypertension.
Our findings of an inverse association of total dairy and 
different types of dairy products with incident diabetes 
are consistent with most32–34 but not all35 previous meta- 
analyses. The meta- analysis by Chen et al35 represented 
mostly high- income countries and more homogeneous 
populations, whereas PURE covers substantially more 
diverse populations and broad patterns of diet globally. 
Further, high income countries consume higher amounts 
of dairy (mainly low fat) than other parts of the world. The 
background diet also varies across countries, whereby in 
high income countries the major problem is over nutri-
tion, while in low income countries, there is more under 
nutrition and people consume low amounts of dairy and 
a higher amount of refined carbohydrates. Therefore, the 
findings from a previous meta- analysis may not be appli-
cable to other parts of the world, although our findings 
were robust in different populations with varying levels 
of dairy intake. In a recent meta- analysis, blood fatty 
acids commonly found in dairy foods were associated 
with lower diabetes risk.36 However, a recent Mendelian 
randomization study did not find support for an associa-
tion of milk intake with diabetes risk.37 Collectively, the 
evidence suggests a need for large randomized trials of 
dairy intake, including an evaluation of different types 
of dairy (fermented vs non- fermented) and fat content 
(whole fat vs low fat) in relation to incident diabetes.
Possible pathways for metabolic benefits of dairy 
include angiotensin converting enzyme, peroxisome 
proliferator activated receptors, hepatic de novo lipo-
genesis, hepatic and adipose fatty acid oxidation, and 
inflammation.10 Further, bioactive peptides or amino 
acids produced through yogurt or cheese fermentation 
improves insulin sensitivity, while branched chain amino 
acids in whey has been shown to improve postprandial 
insulin response.38
Our study is among the first large multinational cohort 
studies to examine the association of dairy intake with 
prevalence of MetS and risk of diabetes and hyperten-
sion. We used standardized methods to measure diet 
using country specific validated FFQs and standardized 
methods to obtain information on health measures and 
record new cases of hypertension and diabetes during 
follow- up.
There are some potential limitations. First, diet was 
self- reported and variations in reporting might lead to 
random errors that could dilute real associations between 
dairy intake and health outcomes. Further, misclassifica-
tion of dairy intake cannot be ruled out as we did not 
have repeat measures of diet. However, we found that 
the association between milk intake, recorded at three 
10 BMJ Open Diab Res Care 2020;8:e000826. doi:10.1136/bmjdrc-2019-000826
Epidemiology/Health Services Research
years of follow- up, and cardiovascular disease was similar 
to the analyses using the baseline information,19 indi-
cating that repeat dietary measures are unlikely to alter 
our findings. Second, we could not assess incident MetS 
as several of its components (waist circumference, blood 
glucose, and blood lipids) were assessed in only a random 
20% of the study population during follow- up. For the 
analyses of dairy versus incident hypertension, 25 287 
individuals were excluded because blood pressure was 
not recorded in all participants during follow- up. The 
blood pressure measures during follow- up were carried 
out systematically in all participants in 16 countries or in 
a random 20% of participants in five countries. The char-
acteristics of individuals without blood pressure measures 
during follow- up compared with individuals with blood 
pressure measures during follow- up were similar (online 
appendix table S2). Third, the possibility of residual 
confounding cannot be completely ruled out in obser-
vational studies (eg, dairy intake might be a proxy for 
poverty or access to healthcare). However, our results 
persisted despite extensive adjustments for all known 
confounders, including the use of five markers of socio-
economic status (education, wealth, occupation, urban/
rural location, and geographical location). Additionally, 
we adjusted for study center as a random effect, which 
takes into account socioeconomic factors and clustering 
by community, leading to comparisons within countries 
(see supplemental methods in the online supplemen-
tary appendix). Lastly, the impact of higher dairy intake 
may be influenced by the overall diet, even though anal-
yses are adjusted for multiple dietary confounders and 
conducted within different strata. However, the consis-
tency of results across regions with markedly different 
levels of dairy intake makes it less likely that confounders 
including the background diet, which are expected to 
vary in different regions, explain our observations.
In conclusion, we report that intake of dairy products, 
especially whole fat products, is associated with lower 
prevalence of MetS and its individual components at 
baseline, and a lower risk of hypertension and diabetes 
during follow- up. If our findings are confirmed in suffi-
ciently large and long term trials, then increasing dairy 
consumption may represent a feasible and low cost 
approach to reducing MetS, hypertension, diabetes, and 
ultimately cardiovascular disease events worldwide.
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